Used in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, this compound acts as a multi-kinase inhibitor, targeting tumor cell proliferation and angiogenesis. It interferes with key signaling pathways, including Raf kinase and receptor tyrosine kinases like VEGFR and PDGFR, which are involved in cancer growth and spread. Commonly prescribed when other therapies fail, it helps prolong progression-free survival in eligible patients. Also investigated in other solid tumors and combination therapies for enhanced efficacy.